These medications regulate blood sugar levels, promote feeling of fullness, and support weight loss by mimicking hormones that stimulate insulin release
These effects were compared to those of untreated controls that were also maintained on a high-fat diet
Individual results vary, but 85-95% of patients lose at least 5% of their body weight
GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)commonly affect bowel movements, though responses vary widely among patients
Researchers are finding that GLP-1 agonists influence multiple pathways involved in inflammation, cardiovascular health, mood, motivation and rewardbenefits that appear to extend beyond the downstream effects of weight loss alone
Their A1C levels also dropped by an average of 1.3 to 1.6 percent, depending on dosage